

Published in final edited form as:

Alzheimers Dement. 2014 May ; 10(3): 366–371. doi:10.1016/j.jalz.2013.02.010.

Variants in *PPP3R1* and *MAPT* are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study

David Peterson^{1,*}, Caitlin Munger^{1,*}, Jared Crowley¹, Chris Corcoran^{2,3}, Carlos Cruchaga⁴, Alison M. Goate^{4,5}, Maria C. Norton^{3,6,7}, Robert C. Green⁸, the Alzheimer's Disease Neuroimaging Initiative[¶], Ronald G. Munger⁹, John C.S. Breitner¹⁰, Kathleen A. Welsh-Bohmer¹¹, Constantine Lyketsos¹², JoAnn Tschanz^{3,7}, and John S.K. Kauwe¹

¹Department of Biology, Brigham Young University, Provo, UT

²Department of Mathematics and Statistics, Utah State University, Logan, UT

³Center for Epidemiologic Studies, Utah State University, Logan, UT

⁴Department of Psychiatry, Washington University School of Medicine, St. Louis, MO

⁵Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO

⁶Department of Family Consumer and Human Development, Utah State University, Logan, UT

⁷Department of Psychology, Utah State University, Logan, UT

⁸Division of Genetics, Department of Medicine and Partners Center for Personalized Genetic Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

⁹Department of Nutrition Dietetics and Food Sciences, Utah State University, Logan, UT

¹⁰Department of Psychiatry, McGill University, Montreal, Canada

¹¹Departments of Psychiatry and Medicine, Duke University, Durham NC

¹²Department of Psychiatry, Johns Hopkins Bayview Medical Center, Baltimore, MD

Abstract

© 2013 Elsevier Inc. All rights reserved.

Corresponding Authors: John S.K. Kauwe, PhD, Assistant Professor, Department of Biology, Brigham Young University, Provo, UT 84602. kauwe@byu.edu Phone: 801-422-2993 Fax: 801-422-0090, JoAnn T. Tschanz, PhD, Professor, Department of Psychology, Utah State University, Logan, UT 84322. joann.tschanz@usu.edu Phone: 435-797-1583 Fax: 435-797-2771.

*These authors contributed equally to this work.

¶Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.ucla.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Background—SNPs located in the gene encoding the regulatory subunit of the protein phosphatase 2B (*PPP3R1*, rs1868402) and the microtubule-associated protein tau (*MAPT*, rs3785883) gene were recently associated with higher cerebrospinal fluid (CSF) tau levels in samples from the Knight Alzheimer's Disease Research Center at Washington University (WU) and Alzheimer's Disease Neuroimaging Initiative (ADNI). In these same samples these SNPs were also associated with faster functional decline, or progression of Alzheimer's disease (AD) as measured by the Clinical Dementia Rating sum of boxes scores (CDR-sb). We attempted to validate the latter association in an independent, population-based sample of incident AD cases from the Cache County Dementia Progression Study (DPS).

Methods—All 92 AD cases from the DPS with a global CDR-sb = 1 (mild) at initial clinical assessment who were later assessed on CDR-sb data on at least two other time points were genotyped at the 2 SNPs of interest (rs1868402 and rs3785883). We used linear mixed models to estimate associations between these SNPs and CDR-sb trajectory. All analyses were performed using Proc Mixed in SAS.

Results—While we observed no association between rs3785883 or rs1868402 alone and change in CDR-sb ($p > 0.10$), there was a significant association between a combined genotype model and change in CDR-sb: carriers of the high-risk genotypes at both loci progressed more than 2.9 times faster than non-carriers ($p = 0.015$). When data from DPS were combined with previously published data from WU and ADNI, change in CDR-sb was 30% faster for each copy of the high-risk allele at rs3785883 ($p = 0.0082$) and carriers of both high-risk genotypes at both loci progressed six times faster ($p < 0.0001$) than all others combined.

Conclusions—We replicate a previous report by Cruchaga et al that specific variations in rs3785883 and rs1868402 are associated with accelerated progression of AD. Further characterization of this association will provide a better understanding of how genetic factors influence the rate of progression of Alzheimer's disease and could provide novel insights into preventative and therapeutic strategies.

Keywords

Alzheimer's disease; genetics; association; rate of progression; *PPP3R1*; *MAPT*

Introduction

Alzheimer's disease (AD) is the most common neurodegenerative disease, affecting over 5 million individuals in the USA alone [1]. While the $\epsilon 4$ allele of apolipoprotein E (*APOE*) has been identified as the most robust susceptibility variant in the late-onset form of AD, data from recent genome-wide association studies (GWAS) have been successful in identifying additional genetic factors that influence AD risk [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]. Little is known, however, about genetic factors that influence the rate of progression after the onset of dementia due to AD. Recently, several single-nucleotide polymorphisms (SNPs), located in the genes encoding the regulatory subunit of the protein phosphatase 2B (*PPP3R1*, rs1868402), and the microtubule-associated protein tau (*MAPT*, rs3785883) genes, were associated with increased cerebrospinal fluid tau levels and increased rate of functional decline, or progression of AD as measured by the Clinical Dementia Rating sum

of boxes (CDR-sb) [14, 15]. In this study we attempted to replicate these associations by genotyping these two SNPs in an independent sample of 92 AD cases from the Cache County Dementia Progression Study (DPS) and examining their association with the rate of functional decline or “progression” as measured by the CDR-sb. We then pooled our data with data from the original report on these markers and performed a combined analysis to evaluate the association in the combined sample.

Materials and Methods

Participants

The Cache County Study on Memory, Health, and Aging (CCSMHA) is a population-based epidemiological study of dementia examining both genetic and environmental risk factors, and their interactions. All individuals aged 65 and older and living in Cache County Utah were targeted for enrollment. Beginning in 1995, four triennial waves of dementia ascertainment were completed, with 5,092 (90% of eligible) individuals aged 65 and older participating in a baseline interview. The study employed a multi-stage dementia ascertainment protocol described elsewhere [16]. Briefly, screening began with the Modified Mini-Mental State examination (3MS; [17]) or Informant Questionnaire for Cognitive Decline in the Elderly [18]. “Screened positive” individuals completed an in-depth clinical assessment, including a brief physical evaluation, a detailed history of medical and cognitive symptoms, a structured neurological examination, and a one-hour battery of neuropsychological tests. After psychiatrist examination and neuroimaging in persons with working diagnoses of dementia, an expert panel reviewed all available data and assigned final consensus diagnoses, with AD diagnoses following the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria [19]. A total of 359 prevalent and 583 incident cases of dementia were identified (including 209 prevalent and 335 incident cases of AD). Informed consent was obtained for each interview. Institutional Review Boards at Utah State University, Duke University, and Johns Hopkins University Study approved all study procedures.

All incident AD cases that survived to the commencement of the Cache County Dementia Progression Study (DPS) in 2002 were invited to participate with ongoing enrollment and annual follow-up after dementia onset [20]. Rate of AD progression was based on functional ability as measured by the Clinical Dementia Rating Scale-sum of boxes (CDR-sb). Significant variability in the rate of progression has been previously reported in these individuals, with approximately one third to one half progressing slowly in their disease course, as defined by a one point (or less) per year change in function (CDR-sb) [20]. As in Cruchaga et al., participants were selected to have a global Clinical Dementia Rating (CDR) <1 at their initial clinical assessment to maximize the amount of progression information and to minimize possible floor/ceiling effects from individuals who began the study with advanced levels of dementia. They were also selected to have stored DNA samples and CDR-sb data for at least two later time points. Ninety-two participants with incident AD from the DPS met these criteria. Individuals in this cohort were assessed annually at

regularly scheduled intervals [20]. Demographic information on this cohort can be found in table 1.

Data from the WU and ADNI samples used in our initial study suggesting that variants in *PPP3R1* and *MAPT* are associated with the rate of progression were used for a larger combined analysis. Samples from WU were enrolled in longitudinal studies at the Knight Alzheimer's Disease Research Center. Demographics of this sample are in table 1 and sample collection and ascertainment has been described previously [21]. The ADNI samples are part of a longitudinal study designed to measure the progression of mild cognitive impairment (MCI) and early AD. Like the DPS samples, both the WU and ADNI samples have been assessed using CDR and CDR-sb data for each sample have been used in this manuscript. Demographics can be found in table 1 and sample collection and ascertainment has been described previously [22, 23]. For up-to-date information, see www.adni-info.org.

Genotyping

For the WU series genotyping of rs1868402 and rs3785883 was conducted on DNA from blood samples using an Illumina Golden Gate custom genotyping chip [15]. Genotypes were called using BeadStudio. The DNA from the ADNI samples was obtained from cell lines at the National Cell Repository for Alzheimer's Disease and was also genotyped previously, using Taqman® Assays [15]. For the DPS samples DNA from buccal cells was genotyped rs1868402 and rs3785883 and used the same Taqman® Assays as were used for the ADNI samples, which are available to be ordered from Life Technologies (rs1868402 assay id C__12044272_10, rs3785883 assay id C__27500834_10). Genotype calls from Taqman® Assays were made using Genotyper using all the genetic data from the DPS study. DNA from the DPS samples was genotyped in duplicate and concordance rates were 100%. Genotyping rates in all samples attempted were 98.6%. Genotype frequencies for these SNPs did not deviate significantly from the expectations of Hardy-Weinberg equilibrium (evaluated using a chi-squared test to compare the observed vs. the expected genotype frequencies).

Analysis

We first conducted analyses in the DPS samples alone, then in the combined DPS, WU and ADNI samples. Our analyses were limited *a priori* to three tests; the two single SNPs and the specific combined genetic model that we identified in our previous report [15]. Specifically, we used linear mixed models to estimate associations between specific SNPs and CDR-sb trajectory to test the dominant model for rs1868402, the additive model for rs3785883 and the exact combined genotype model specified in Cruchaga et al, 2010 [15]. In all analyses, initial age and initial CDR were included as covariates. *APOE* ϵ 4 genotype and gender were not included as covariates as they were not associated with rate of progression. All samples reported European-American ancestry. Analyses of these samples using array data from WU, ADNI and DPS indicate no evidence of population substructure. The DPS is population-based sample and there is a limited amount of relatedness among individuals. We corrected for possible family-based effects in the DPS sample by adding random effect for family to the model. The p-values with and without inclusion of this variable, *APOE* genotype, or gender were affected minimally. The combined DPS, WU and

ADNI analysis included site in addition to initial CDR and initial age as a variable in the model. For further characterization of significant association we performed analyses of the highest risk genotype combination against the reference group of all other individuals and tested an rs1868402*rs3785883 interaction term. All analyses were performed using Proc Mixed in the SAS software package (SAS Institute Inc., Cary, NC, USA).

Results

DPS participants had a mean initial age of 84.5 years, 45% were male, and 47% were *APOE* ε4 carriers. Mean number of assessments was 4, and mean time from first to final assessment was 3.2 years. The ADNI sample has significantly shorter follow-up time than the other samples ($p < 0.05$) and the DPS sample is significantly older ($p < 0.0001$). The minor allele frequency of rs1868402 in the DPS participants (0.28) was similar to that observed in the pooled WU and ADNI cohorts (0.27) and in the 1,000 Genomes Project (0.25). The same was true for the minor allele frequency of rs3785883: 0.19 in DPS, 0.17 in the WU and ADNI data (0.17) and 0.17 in the 1000 Genomes Project. Genotype frequencies for both rs1868402 and rs3785883 (table 1) were not significantly different from each other ($p = 0.28$, 0.21, respectively) and did not deviate from the expectations of Hardy-Weinberg equilibrium ($p > 0.05$). The average rate of functional decline in the DPS cohort DPS was 1.35 CDR-sb per year (sbpy). A summary of the associations observed in the DPS alone, combined WU and ADNI samples (reported previously) and the DPS, WU, ADNI combined series are in table 2. In the DPS samples there was not a significant association between rs1868402 (dominant model; $p = 0.55$) or rs3785883 (additive model; $p = 0.075$) and increased rate of change in CDR-sb. For rs3785883 increased rate of progression with each copy of the “A” allele observed was consistent with findings of Cruchaga et al (2010). In the DPS samples alone, the combined genotype model was significantly associated with change in CDR-sb: carriers of the risk genotype at both loci progressed more than 2.9 times faster than all other individuals ($p = 0.029$, 3.61 sbpy). Analyses using *APOE* genotype, gender, and “family” as covariates did not significantly change our results.

When the DPS cohort was combined with those from the WU and ADNI series [15] the average rate of change was 0.42 sbpy. In this combined sample there was no association between rs1868402 and rate of progression ($p = 0.24$). However, there was a significant association between rs3785883 and progression: participants progressed 30% faster on average for each copy of the risk allele compared to those lacking the risk allele ($p = 0.008$; no risk alleles 0.37 sbpy, 1 risk allele 0.49 sbpy, 2 risk alleles 0.61 sbpy; table 3). Carriers of risk genotypes at both loci progressed six times faster on CDR-sb than carriers of all other genotypes combined (2.37 sbpy for risk genotypes, 0.39 sbpy for all others; $p < 0.0001$; table 3). In addition, non-carriers of either risk genotype showed a 20% slower rate of progression compared to all other individuals that neared statistical significance ($p = 0.084$; 0.37 sbpy for non-carriers, 0.46 sbpy for all others; table 3). Analysis using an rs1868402*rs3785883 interaction term also yielded a significant interaction ($p = 0.049$). Analyses using *APOE* genotype and/or gender as a covariate did not significantly change our results.

Discussion

Specific genetic variants in *PPP3R1* and *MAPT* may modulate levels of tau and ptau in the presence of amyloid deposition, thus altering the rate of functional decline in individuals with AD [14, 15]. The results reported here provide additional evidence from an independent sample that AD cases who carry the “C” allele of rs1868402 (*PPP3R1*) and are homozygous for the “A” allele at rs3785883 (*MAPT*) have a significantly faster functional decline.

The DPS sample was older at initial assessment than the WU and ADNI samples ($p < 0.0001$). Small sample size and greater initial age may have limited the statistical power of the analyses in the DPS sample alone and may explain the failure to detect significant associations in single SNP tests (power=0.29). Despite this, the findings for the additive model of rs3785883 were suggestive of association. The direction of the effect observed in DPS alone for both single SNP tests was consistent with the results reported by Cruchaga et al. In addition, results from DPS alone suggested that individuals carrying high-risk genotypes at both markers progressed 2.9 times faster than individuals with other genotypes.

Combined analyses of the three datasets provided greater power (0.96) and evidence of greater acceleration of decline for carriers of high-risk alleles at both rs1868402 and rs3785883 resulting in a six times faster rate of progression of Alzheimer’s disease as measured by the CDR-sb. This appears to be more than a simple additive effect, such that these genes interact to produce the observed phenotypic effect ($p = 0.0498$). We also note that in combined analysis, carriers of the non-risk genotypes at both loci (GG for rs1868402 and TT for rs3785883) progressed 20% slower than all other individuals (figure 1).

Our data are consistent with other recent work indicating that these markers play an important role in the rate of dementia progression in individuals diagnosed with AD. The original report provides evidence that the mechanism of this effect is altered levels of tau in the brain. Other work also supports role for ptau levels in AD progression. For example, CSF ptau levels have been shown to increase over time in impaired patients [24]. More recently, Liu et al (2012) showed trans-synaptic spread of tau pathology in mouse models, providing direct evidence that tau is an important aspect of early AD pathology and progression. In addition to tau and AD pathology, significant efforts to identify factors that modulate AD progression are also ongoing. Recently, associations between the CSF VILIP levels [25] and CSF CCL2 levels and AD progression have been reported [26]. While this study was limited to European Americans, further study of AD progression in larger datasets from multiple ethnic groups will provide better understanding of the pathological and genetic basis for both faster and slower progression, thus elucidating novel therapeutic targets for Alzheimer’s disease.

Acknowledgments

This work was supported by the Alzheimer’s Association (MNIRG-11-205368), the BYU Gerontology Program and the National Institutes of Health (R01-AG11380, R01-AG021136, P30-NS069329-01, R01-AG042611). The Institutional Review Boards of each appropriate institution approved sample and data collection. The authors gratefully acknowledge the individuals who participated in this study without whom this work would not have been possible.

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amofix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the ADNI is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the Rev August 16 2011 University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, R01 HG02213, U01 AG024904, U01 HG006500, K24 AG027841, R01 HG005092, P50AG005146, and the Dana Foundation.

References

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. *Arch Neurol.* 2003; 60:1119–1122. [PubMed: 12925369]
2. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. *Am J Hum Genet.* 2009; 84:35–43. [PubMed: 19118814]
3. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am J Hum Genet.* 2008; 83:623–632. [PubMed: 18976728]
4. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. *Nat Genet.* 2009; 41:192–198. [PubMed: 19136949]
5. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. *J Clin Psychiatry.* 2007; 68:613–618. [PubMed: 17474819]
6. Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, et al. Examination of the current top candidate genes for AD in a genome-wide association study. *Mol Psychiatry.* 2009
7. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet.* 2009; 41:1088–1093. [PubMed: 19734902]
8. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet.* 2011; 43:429–435. [PubMed: 21460840]
9. Jun G, Naj AC, Beecham GW, Wang LS, Buross J, et al. Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. *Arch Neurol.* 2010
10. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet.* 2009; 41:1094–1099. [PubMed: 19734903]
11. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. *Arch Neurol.* 2008; 65:45–53. [PubMed: 17998437]
12. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet.* 2011; 43:436–441. [PubMed: 21460841]

13. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. *Jama*. 2010; 303:1832–1840. [PubMed: 20460622]
14. Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. *Proc Natl Acad Sci U S A*. 2008; 105:8050–8054. [PubMed: 18541914]
15. Cruchaga C, Kauwe JSK, Mayo K, Spiegel N, Bertelsen S, et al. SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease. *PLoS Genet*. 2010; 6:e1001101. [PubMed: 20862329]
16. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. *Neurology*. 1999; 53:321–331. [PubMed: 10430421]
17. Tschanz JT, Welsh-Bohmer KA, Plassman BL, Norton MC, Wyse BW, et al. An adaptation of the modified mini-mental state examination: analysis of demographic influences and normative data: the cache county study. *Neuropsychiatry Neuropsychol Behav Neurol*. 2002; 15:28–38. [PubMed: 11877549]
18. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. *Psychol Med*. 1989; 19:1015–1022. [PubMed: 2594878]
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984; 34:939–944. [PubMed: 6610841]
20. Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, et al. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. *Am J Geriatr Psychiatry*. 2011; 19:532–542. [PubMed: 21606896]
21. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. *Arch Neurol*. 2009; 66:638–645. [PubMed: 19433664]
22. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology*. 74:201–209. [PubMed: 20042704]
23. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, et al. The Alzheimer's disease neuroimaging initiative. *Neuroimaging Clin N Am*. 2005; 15:869–877. xi–xii. [PubMed: 16443497]
24. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, et al. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. *Neurobiol Aging*. 2008; 29:1466–1473. [PubMed: 17512092]
25. Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM, et al. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. *Neurology*. 78:709–719. [PubMed: 22357717]
26. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, et al. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. *PLoS ONE*. 7:e30525. [PubMed: 22303443]




Figure 1.

Rate of progression over a five-year time period genotype groups in the combined WU, ADNI, DPS sample. (A) rs1868402 (dominant model) (B) rs3785883 (additive model), and (C) combined genotypes (carriers of both risk genotypes are compared to all other genotype combinations). Error bars represent the standard error in change in CDR-sb over time.

Table 1

Sample Characteristics: sample size (N), age at first study assessment (initial age), percentage of males (%Males), percentage of *APOE* ϵ 4 carriers (% ϵ 4 Positive), mean and standard deviation for the number of assessments (# Assessments), the mean and standard deviation of the Follow-up time and genotype frequencies (%) for rs1868402 and rs3785883 for the Cache County Dementia Progression Study (DPS), Alzheimer's Disease Neuroimaging Initiative (ADNI) and Washington University (WU) series.

	DPS	ADNI	WU
N	92	459	109
Initial Age	84.5(5.3)	75(6)	68(11)
%Male	45	39	56
% ϵ 4 Positive	47	47	40
# Assessments	4.0(2.4)	4.1(1.6)	3.8(2.0)
Follow-up time	3.2(2.1)	1.9(1.1)	3.2(2.1)
rs1868402 (CC/CT/TT)	5/46/49	7/40/53	10/44/46
rs3785883 (AA/AG/GG)	5/27/58	3/30/67	2/25/73

P-value, risk genotype and change in CDR-sb per year for the dominant model of rs1868402, the additive model of rs3785883 and the combined genotype model for rs1868402/rs3785883. Values are listed for the Dementia Progression Study (DPS) alone, the Washington University (WU) and Alzheimer's Disease Neuroimaging Initiative (ADNI) samples combined and the combined DPS, WU and ADNI samples.

Table 2

	rs1868402		rs3785883		Combined Model	
	risk geno/sbpy	p-value	risk geno/sbpy	p- value	risk geno/sbpy	p-value
DPS	CC+CT/1.38	0.55	AA/1.91	0.075	CC+CT, AA/3.61	0.029
*WU/ADNI	CC+CT/0.29	0.0026	AA/0.34	0.057	CC+CT, AA/1.02	<0.0001
DPS/WU/ADNI	CC+CT/0.43	0.24	AA/0.61	0.008	CC+CT, AA/2.39	<0.0001

* WU/ADNI results were previously reported by Cruchaga et al (2010).

Table 3

Change in CDR-sb per year for select genotypes compared to all other genotypes in the combined WU, ADNI and DPS samples.

	Risk genotype	All others	P-value
rs1868402	0.43	0.37	0.243
rs3785883	0.61	**0.37	***0.008
Combined Model	2.37	0.39	<0.0001
Combined Model	*0.37	0.46	0.084

* Value is for the *non-risk* genotype carriers.

** Value for the *non-risk* genotype from the additive model.

*** P-value from the additive model.